Breast Cancer

Daniel A. Osman, MD, a South Florida surgeon who founded the Miami Breast Cancer Conference® and helped shepherd its growth into a premier medical meeting, died peacefully in Weston, Florida, on July 15 at the age of 98.

Angela DeMichele, MD, MSCE, shares how to utilize available data with CDK4/6 inhibitors in the neoadjuvant and adjuvant settings to optimize outcomes for patients with hormone receptor–positive breast cancer.

The growing number of treatments within the HER2-positive breast cancer armamentarium signals a need to redefine and tailor neoadjuvant and adjuvant strategies to individual patients.

The optimal sequence of therapies for patients with metastatic HER2-positive breast cancer must be an individualized one, and should be dependent on the presence and/or level of central nervous system disease.

Brian Czerniecki, MD, PhD, discusses the importance of utilizing a multidisciplinary effort to treat patients with breast cancer who develop brain or central nervous system metastases.

Charles E. Geyer, Jr, MD, discusses the state of HER2-positive breast cancer, the significance of the results of the DESTINY-Breast01 trial, and symptoms that could be an early indicator of interstitial lung disease.

Anthracycline-based chemotherapy followed by ado-trastuzumab emtansine plus pertuzumab did not show statistically significant or clinically meaningful improvement in invasive disease-free survival in patients with high-risk HER2-positive early breast cancer, missing the primary end point of the phase 3 KAITLIN trial.

Heather Han, MD, discusses ongoing clinical trials within the field of HER2-positive breast cancer and the future of personalized treatment for this patient population.

Kamran A. Ahmed, MD, discusses key strategies to manage patients with breast cancer and brain metastases.

Christine Sam, MD, discusses strategies to prevent the spread of COVID-19 in geriatric patients with cancer and shared advice on how to overcome unique challenges faced in the care of this population.

William J. Gradishar, MD, discusses the activity of trastuzumab deruxtecan in patients with metastatic HER2-positive breast cancer and the importance of building experience with the drug before evaluating it in combination or moving it into earlier lines of therapy.

Ian E. Krop, MD, PhD, discusses the pivotal data from the DESTINY-Breast01 trial, the need for longer-term follow-up with trastuzumab deruxtecan, and the proper management of interstitial lung disease.

The 2020 ASCO Virtual Scientific Program delivered a number of important updates to the field of breast cancer, explained Joyce A. O'Shaughnessy, MD.

Efbemalenograstim alpha (F-627) has demonstrated strong and lasting benefit when used as a treatment for chemotherapy-induced neutropenia in patients with breast cancer, meeting the primary and secondary end points of a phase 3 study.